Showing 1 - 4 of 4
New drug to be registered with FDA
News, Apinya Wipatayotin, Published on 04/07/2025
» The Government Pharmaceutical Organisation (GPO) has prepared to register the affordable hepatitis C drug ravidasvir with the Food and Drug Administration to improve access for 800,000 patients and reduce treatment costs.
Unite to solve neglected diseases
Oped, Published on 29/04/2025
» The successful collaboration between the health ministries of Malaysia and Thailand, industry partners in Egypt and Malaysia, and the Drugs for Neglected Diseases initiative (DNDi) to bring a new hepatitis C antiviral drug -- ravidasvir -- to market in 2022 was an important milestone. For years, a 12-week course of treatment using sofosbuvir cost between $70,000 (2.34 million baht) and $80,000, putting it out of reach for many in the Global South. But ravidasvir -- a safe and effective alternative when combined with sofosbuvir -- costs far less, averaging less than $500 per course.
Hep C meds urged for HIV patients
News, Post Reporters, Published on 28/07/2018
» Health networks have called on authorities to ensure patients with HIV/Aids have more access to medicine for the treatment of hepatitis C.
Low-cost Hep C cure showing good results
News, Apinya Wipatayotin, Published on 08/05/2018
» The first phase of clinical tests for an affordable Hepatitis C treatment has yielded a high cure rate, according to the Department of Disease Control.